Understanding the broad-spectrum neuroprotective action profile of green tea polyphenols in aging and neurodegenerative diseases

Journal of Alzheimer's Disease

Volumn 25, Issue 2, 2011, Pages 187-208

  Mandel, Silvia A ^a   Amit, Tamar ^a   Weinreb, Orly ^a   Youdim, Moussa B H ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Alzheimer's disease; combination therapy; green tea polyphenols; hypoxia inducible factor; iron chelation; neuroprotection neurorescue; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ANTIOXIDANT; BLACK TEA EXTRACT; CATECHIN; DOPAMINE RECEPTOR STIMULATING AGENT; EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; FOLIC ACID; GREEN TEA EXTRACT; HYPOXIA INDUCIBLE FACTOR 1; LEVODOPA; NUTRACEUTICAL; POLYPHENOL; PROTEIN KINASE C; PYRIDOXINE; S ADENOSYLMETHIONINE; TAU PROTEIN;

AGING; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; APOPTOSIS; CELL SURVIVAL; COGNITIVE DEFECT; DEGENERATIVE DISEASE; HUMAN; IRON CHELATION; LEWY BODY; NERVE CELL; NERVE REGENERATION; NEUROPROTECTION; NONHUMAN; NUTRITION; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TEA;

EID: 79960722781     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-101803     Document Type: Review

References (178)

1. Mandel S, Grunblatt E, Riederer P, Gerlach M, Levites Y, Youdim MBH (2003) Neuroprotective strategies in Parkinson's disease: an update on progress. CNS Drugs 17, 729-762. (Pubitemid 37000010)
2. Dauer W, Przedborski S (2003) Parkinson's disease: mechanisms and models. Neuron 39, 889-909. (Pubitemid 37130207)
3. Farlow MR, Miller ML, Pejovic V(2008) Treatment options in Alzheimer's disease: maximizing benefit, managing expectations. Dement Geriatr Cogn Disord 25, 408-422. (Pubitemid 351630074)
4. Luchsinger JA, Tang MX, Shea S, Mayeux R (2003) Antiox-idant vitamin intake and risk of Alzheimer disease. Arch Neurol 60, 203-208. (Pubitemid 36193963)
5. Morris MC, Beckett LA, Scherr PA, Hebert LE, Bennett DA, Field TS, Evans DA (1998) Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. Alzheimer Dis Assoc Disord 12, 121-126. (Pubitemid 29154978)
6. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 336, 1216-1222. (Pubitemid 27183651)
7. Graham DJ (2006) COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense. JAMA 296, 1653-1656. (Pubitemid 44511613)
8. Isaac MG, Quinn R, Tabet N (2008) Vitamin E for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev, CD002854.
9. Malouf R, Grimley Evans J(2008) Folic acid withor without vitamin B12 for the prevention and treatment of healthy elderly and demented people. Cochrane Database Syst Rev, CD004514.
10. Storch A, Jost WH, Vieregge P, Spiegel J, Greulich W, Durner J, Muller T, Kupsch A, Henningsen H, Oertel WH, Fuchs G, Kuhn W, Niklowitz P, Koch R, Herting B, Reichmann H (2007) Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol 64, 938-944. (Pubitemid 47047992)
11. The Parkinson Study Group (1993) Effectsoftocopherol and deprenylonthe progression ofdisabilityinearly Parkinson's disease. N Engl J Med 328, 176-183.
12. Standridge JB (2004) Pharmacotherapeutic approaches to the treatmentof Alzheimer's disease. Clin Ther26, 615-630.
13. Stoessl J (2008) Potential therapeutic targets for Parkinson's disease. Expert Opin Ther Targets 12, 425-436.
14. Schapira AH, Agid Y, Barone P, Jenner P, Lemke MR, Poewe W, Rascol O, Reichmann H, Tolosa E (2009) Perspectives on recent advances in the understanding and treatment of Parkinson's disease. Eur J Neurol 16, 1090-1099.
15. Chan A, Paskavitz J, Remington R, Rasmussen S, Shea TB (2008) Efficacy of a vitamin/nutriceutical formulation for early-stage Alzheimer's disease: a 1-year, open-label pilot study with an 16-month caregiver extension. Am J Alzheimers Dis Other Demen 23, 571-585.
16. Remington R, Chan A, Paskavitz J, Shea TB (2009) Efficacy of a vitamin/nutriceutical formulation for moderate-stage to later-stage Alzheimer's disease: a placebo-controlled pilot study. Am J Alzheimers Dis Other Demen 24, 27-33.
17. Cornelli U (2010) Treatment of Alzheimer's disease with a cholinesterase inhibitor combined with antioxidants. Neu-rodegener Dis 7, 193-202.
18. Ravina BM, Fagan SC, Hart RG, Hovinga CA, Murphy DD, Dawson TM, Marler JR (2003) Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 60, 1234-1240. (Pubitemid 36460976)
19. Investigators NN-P (2007) A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 68, 20-28.
20. PSG (2006) A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66, 664-671.
21. Gordon PH, Cheung YK, Levin B, Andrews H, Doorish C, Macarthur RB, Montes J, Bednarz K, Florence J, Rowin J, Boylan K, Mozaffar T, Tandan R, Mitsumoto H, Kelvin EA, Chapin J, Bedlack R, Rivner M, McCluskey LF, Pestronk A, Graves M, Sorenson EJ, Barohn RJ, Belsh JM, Lou JS, Levine T, Saperstein D, Miller RG, Scelsa SN (2008) A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. Amyotroph Lateral Scler 9, 212-222.
22. Khokhar S, Magnusdottir SG (2002) Total phenol, catechin, and caffeine contents of teas commonly consumed in the United Kingdom. J Agric Food Chem 50, 565-570. (Pubitemid 34106679)
23. Higdon JV, Frei B (2003) Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr 43, 89-143. (Pubitemid 38552312)
24. Mandel SA, Amit T, Weinreb O, Reznichenko L, Youdim MB (2008) Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson diseases. CNS Neu-rosci Ther 14, 352-365.
25. Perron NR, Brumaghim JL (2009) A review of the antioxi-dant mechanisms of polyphenol compounds related to iron binding. Cell Biochem Biophys 53, 75-100.
26. Amit T, Avramovich-Tirosh Y, Youdim MB, Mandel S (2008) Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators. FASEB J 22, 1296-1305. (Pubitemid 351656771)
27. Lin LC, Wang MN, Tseng TY, Sung JS, Tsai TH (2007) Pharmacokinetics of (-)-epigallocatechin-3-gallate in conscious and freely moving rats and its brain regional distribution. J Agric Food Chem 55, 1517-1524.
28. Suganuma M, Okabe S, Oniyama M, Tada Y, Ito H, Fujiki H (1998) Wide distribution of [3 H](-)-epigallocatechin gal-late, a cancer preventive tea polyphenol, in mouse tissue. Carcinogenesis 19, 1771-1776. (Pubitemid 28476352)
29. Kuriyama S, Hozawa A, Ohmori K, Shimazu T, Matsui T, Ebihara S, Awata S, Nagatomi R, Arai H, Tsuji I (2006) Green tea consumption and cognitive function: a cross-sectional study from the Tsurugaya Project 1. Am J Clin Nutr 83, 355-361. (Pubitemid 44713198)
30. Ng TP, Feng L, Niti M, Kua EH, Yap KB (2008) Tea consumption and cognitive impairment and decline in older Chinese adults. Am J Clin Nutr 88, 224-231. (Pubitemid 351988703)
31. Huang CQ, Dong BR, Zhang YL, Wu HM, Liu QX (2009) Association of cognitive impairment with smoking, alcohol consumption, tea consumption, and exercise among Chinese nonagenarians/centenarians. Cogn Behav Neurol 22, 190-196.
32. Checkoway H, Powers K, Smith-Weller T, Franklin GM, Longstreth WT Jr, Swanson PD (2002) Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am J Epidemiol 155, 732-738. (Pubitemid 34297653)
33. Hu G, Bidel S, Jousilahti P, Antikainen R, Tuomilehto J (2007) Coffee and tea consumption and the risk of Parkinson's disease. Mov Disord 22, 2242-2248.
34. Tan LC, Koh WP, Yuan JM, Wang R, Au WL, Tan JH, Tan EK, Yu MC (2008) Differential effects of black versus green tea on risk of Parkinson's disease in the Singapore Chinese Health Study. Am J Epidemiol 167, 553-560. (Pubitemid 351323310)
35. Kandinov B, Giladi N, Korczyn AD (2009) Smoking and tea consumption delay onset of Parkinson's disease. Parkin-sonism Relat Disord 15, 41-46.
36. Olanow CW, Hauser RA, Jankovic J, Langston W, Lang A, Poewe W, Tolosa E, Stocchi F, Melamed E, Eyal E, Rascol O (2008) A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord 23, 2194-2201.
37. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E (2009) A double-blind, delayed-start trial of rasag-iline in Parkinson's disease. N Engl J Med 361, 1268-1278.
38. Chan P, Qin Z, Zheng Z, Zhang L, Fang X, Sun F, Gu Z, Chen S, Ma J, Meng C, Langston JW, Tanner CM (2009) A randomized, double-blind, placebo controlled, delayed start study to assess safety, tolerability and efficacy of green tea polyphenols in Parkinson's disease. XVIII WFN World Congress on Parkinson's Disease and Related Disorders, Miami Beach, FL, USA, December 13-16, 2009.
39. Kumari MV, Yoneda T, Hiramatsu M (1997) Effect of "beta CATECHIN" on the life span of senescence accelerated mice (SAM-P8 strain).Biochem Mol Biol Int41, 1005-1011.
40. Li Q, Zhao HF, Zhang ZF, Liu ZG, Pei XR, Wang JB, Li Y (2009) Long-term green tea catechin administration prevents spatial learning and memory impairment in senescence-accelerated mouse prone-8 mice by decreasing Abeta1-42 oligomers and upregulating synaptic plasticity-related proteins in the hippocampus. Neuroscience 163, 741-749.
41. Li Q, Zhao HF, Zhang ZF, Liu ZG, Pei XR, Wang JB, Cai MY, Li Y (2009) Long-term administration of green tea catechins prevents age-related spatial learning and memory decline in C57BL/6 Jmiceby regulating hippocampal cyclic amp-response element binding protein signaling cascade. Neuroscience 159, 1208-1215.
42. Assuncao M, Santos-Marques MJ, Carvalho F, Lukoyanov NV, Andrade JP (2009) Chronic green tea consumption prevents age-related changes in rat hippocampal formation. Neurobiol Aging, doi:10.1016/j.neurobiolaging. 2009.03.016
43. He M, Zhao L, Wei MJ, Yao WF, Zhao HS, Chen FJ (2009) Neuroprotective effects of (-)-epigallocatechin-3-gallate on aging mice induced by D-galactose. Biol Pharm Bull 32, 55-60.
44. Zhang L, Jie G, Zhang J, Zhao B (2009) Significant longevity-extending effects of EGCG on Caenorhabditis elegans under stress. Free Radic Biol Med 46, 414-421.
45. Lee S, Suh S, Kim S (2000) Protective effectsofthe green tea polyphenol (-)-epigallocatechin gallate against hippocam-pal neuronal damage after transient global ischemia in gerbils. Neurosci Let 287, 191-194. (Pubitemid 30339381)
46. Sutherland BA, Shaw OM, Clarkson AN, Jackson DM, Sammut IA, Appleton I (2005) Neuroprotective effects of (-)-epigallocatechin gallate after hypoxia-ischemia-induced brain damage: novel mechanisms of action. FASEB J 19, 258-260. (Pubitemid 40189274)
47. Aktas O, Prozorovski T, Smorodchenko A, Savaskan NE, Lauster R, Kloetzel PM, Infante-Duarte C, Brocke S, Zipp F (2004) Green tea epigallocatechin-3- gallate mediates T cellular NF-kappa Binhibition and exerts neuroprotection in autoimmune encephalomyelitis.J Immunol173, 5794-5800. (Pubitemid 39392169)
48. Park JW, Hong JS, Lee KS, Kim HY, Lee JJ, Lee SR (2009) Green tea polyphenol (-)-epigallocatechin gallate reduces matrix metalloproteinase-9 activity following transient focal cerebral ischemia. J Nutr Biochem 21, 1038-1044.
49. Koh SH, Lee SM, Kim HY, Lee KY, Lee YJ, Kim HT, Kim J, Kim MH, Hwang MS, Song C, Yang KW, Lee KW, Kim SH, Kim OH (2006) The effect of epigallocatechin gallate on suppressing disease progression of ALS model mice. Neurosci Lett 395, 103-107. (Pubitemid 43188873)
50. Levites Y, Weinreb O, Maor G, Youdim MBH, Mandel S (2001) Green tea polyphenol (-)- Epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem 78, 1073-1082. (Pubitemid 32823156)
51. Chaturvedi RK, Shukla S, Seth K, Chauhan S, Sinha C, Shukla Y, Agrawal AK (2006) Neuroprotective and neu-rorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Neurobiol Dis 22, 421-434.
52. Reznichenko L, Kalfon L, Amit T, Youdim MB, Mandel SA (2010) Low dosage of Rasagiline and epigallocate-chin gallate synergistically restored the nigrostriatal axis in MPTP-induced parkinsonism. Neurodegener Dis 7, 219-231.
53. Haque AM, Hashimoto M, Katakura M, Tanabe Y, Hara Y, Shido O (2006) Long-term administration of green tea catechins improves spatial cognition learning ability in rats. J Nutr 136, 1043-1047.
54. Haque AM, Hashimoto M, Katakura M, Hara Y, Shido O (2008) Green tea catechins prevent cognitive deficits caused by Abeta(1-40) in rats. J Nutr Biochem 19, 619-626.
55. Lee JW, Lee YK, Ban JO, Ha TY, Yun YP, Han SB, Oh KW, Hong JT (2009) Green tea (-)-epigallocatechin-3-gallate inhibits beta-amyloid-induced cognitive dysfunction through modification of secretase activity via inhibition of ERK and NF-kappa B pathways in mice. J Nutr 139, 1987-1993.
56. Rezai-Zadeh K, Shytle D, Sun N, Mori T, Hou H, Jeanniton D, Ehrhart J, Townsend K, Zeng J, Morgan D, Hardy J, Town T, Tan J (2005) Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci 25, 8807-8814. (Pubitemid 41362059)
57. Lee YK, Yuk DY, Lee JW, Lee SY, Ha TY, Oh KW, Yun YP, Hong JT (2009) (-)-Epigallocatechin-3-gallate prevents lipopolysaccharide-induced elevation of beta-amyloid generation and memory deficiency.Brain Res1250, 164-174.
58. Giunta B, Obregon D, Hou H, Zeng J, Sun N, Nikolic V, Ehrhart J, Shytle D, Fernandez F, Tan J (2006) EGCG mitigates neurotoxicity mediated by HIV-1 proteins gp120 and Tat in the presence of IFN-gamma: role of JAK/STAT1 signaling and implications for HIV-associated dementia. Brain Res 1123, 216-225. (Pubitemid 44794387)
59. Ehrnhoefer DE, Duennwald M, Markovic P, Wacker JL, Engemann S, Roark M, Legleiter J, Marsh JL, Thompson LM, Lindquist S, Muchowski PJ, Wanker EE (2006) Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models. Hum Mol Genet 15, 2743-2751. (Pubitemid 44400401)
60. Kumar P, Kumar A (2009) Protective effects of epigallocat-echin gallate following 3-nitropropionic acid-induced brain damage: possible nitric oxide mechanisms. Psychopharma-cology (Berl) 207, 257-270.
61. Mercer LD, Kelly BL, Horne MK, Beart PM (2005) Dietary polyphenols protect dopamine neurons from oxida-tive insults and apoptosis: investigations in primary rat mesencephalic cultures. Biochem Pharmacol 69, 339-345. (Pubitemid 41556580)
62. Levites Y, Amit T, Youdim MBH, Mandel S (2002) Involvement of protein kinase C activation and cell survival/cell cycle genes in green tea polyphenol (-)-epigallocatechin-3-gallate neuroprotective action. J Biol Chem 277, 30574-30580. (Pubitemid 34970751)
63. Choi YT, Jung CH, Lee SR, Bae JH, Baek WK, Suh MH, Park J, Park CW, Suh SI (2001) The green tea polyphenol (-)-epigallocatechin gallate attenuates beta-amyloid-induced neurotoxicity in cultured hippocampal neurons. Life Sci 70, 603-614. (Pubitemid 34082702)
64. Mandel S, Reznichenko L, Amit T, Youdim MB (2003) Green tea polyphenol (-)-epigallocatechin-3-gallate protects rat PC12 cells from apoptosis induced by serum withdrawal independent of P13-Akt pathway. Neurotox Res 5, 419-424.
65. Ban JY, Jeon SY, Bae K, Song KS, Seong YH (2006) Cate-chin and epicatechin from Smilacis chinae rhizome protect cultured rat cortical neurons against amyloid beta protein (25-35)-induced neurotoxicity through inhibition of cytoso-lic calcium elevation. Life Sci 79, 2251-2259. (Pubitemid 44666063)
66. Reznichenko L, Amit T, Youdim MB, Mandel S (2005) Green tea polyphenol (-)-epigallocatechin-3-gallate induces neurorescue of long-term serum-deprived PC12 cells and promotes neurite outgrowth. J Neurochem 93, 1157-1167. (Pubitemid 40776570)
67. Weinreb O, Amit T, Youdim MB (2007) A novel approach of proteomics and transcriptomics to study the mechanism of action of the antioxidant-iron chelator green tea polyphe-nol (-)-epigallocatechin-3-gallate. Free Radic Biol Med 43, 546-556. (Pubitemid 47058234)
68. Weinreb O, Amit T, Youdim MB (2008) The application of proteomics for studying the neurorescue activity of the polyphenol (-)-epigallocatechin-3- gallate. Arch Biochem Biophys 476, 152-160.
69. Nanjo F, Goto K, Seto R, Suzuki M, Sakai M, Hara Y (1996) Scavenging effects of tea catechins and their derivatives on 1, 1-diphenyl-2-picrylhydrazyl radical. Free Radic Biol Med 21, 895-902. (Pubitemid 26365284)
70. Salah N, Miller NJ, Paganga G, Tijburg L, Bolwell GP, Rice-Evans C (1995) Polyphenolic flavanols as scavengers of aqueous phase radicals and as chain-breaking antioxidants. Arch Biochem Biophy 322, 339-346.
71. Levites Y, Youdim MBH, Maor G, Mandel S (2002) Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappa B (NF-kappa B) activation and cell death by tea extractsinneuronal cultures.Biochem Pharmacol63, 21-29. (Pubitemid 34075289)
72. Guo Q, Zhao B, Li M, Shen S, Xin W (1996) Studies on protective mechanisms of four components of green tea polyphenols against lipid peroxidation in synaptosomes. Biochim Biophys Acta 1304, 210-222. (Pubitemid 26426992)
73. Skrzydlewska E, Augustyniak A, Michalak K, Farbiszewski R (2005) Green tea supplementation in rats of different ages mitigates ethanol-induced changes in brain antioxidant abilities. Alcohol 37, 89-98.
74. Srividhya R, Jyothilakshmi V, Arulmathi K, Senthilkumaran V, Kalaiselvi P (2008) Attenuation of senescence-induced oxidative exacerbations in aged rat brain by (-)-epigallocatechin-3-gallate. Int J Dev Neurosci 26, 217-223.
75. Assuncao M, Santos-Marques MJ, Carvalho F, Andrade JP (2010) Green tea averts age-dependent declineofhippocam-pal signaling systems related to antioxidant defenses and survival. Free Radic Biol Med 48, 831-838.
76. Lin SM, Wang SW, Ho SC, Tang YL (2010) Protective effect of green tea (-)-epigallocatechin-3-gallate against the monoamine oxidase B enzyme activity increase in adult rat brains. Nutrition 26, 1195-1200.
77. Mazzio EA, Harris N, Soliman KF (1998) Food constituents attenuate monoamine oxidase activity and peroxide levels in C6 astrocyte cells. Planta Med 64, 603-606. (Pubitemid 28481470)
78. Kim JS, Kim JM, O JJ, Jeon BS (2010) Inhibition of inducible nitric oxide synthase expression and cell death by (-)-epigallocatechin-3-gallate, a green tea catechin, in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson's disease. J Clin Neurosci 17, 1165-1168.
79. Owuor ED, Kong AN (2002) Antioxidants and oxidants regulated signal transduction pathways. Biochem Pharmacol 64, 765-770. (Pubitemid 35238028)
80. Mann GE, Rowlands DJ, Li FY, de Winter P, Siow RC(2007) Activation of endothelial nitric oxide synthase by dietary isoflavones: role of NO in Nrf2-mediated antioxidant gene expression. Cardiovasc Res 75, 261-274. (Pubitemid 46964821)
81. Perron NR, Hodges JN, Jenkins M, Brumaghim JL (2008) Predicting how polyphenol antioxidants prevent DNA damage by binding to iron. Inorg Chem 47, 6153-6161.
82. Perron NR, Wang HC, Deguire SN, Jenkins M, Lawson M, Brumaghim JL (2010) Kinetics of iron oxidation upon polyphenol binding. Dalton Trans 39, 9982-9987.
83. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR (2004) Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5, 863-873. (Pubitemid 39482155)
84. Moreira PI, Siedlak SL, Aliev G, Zhu X, Cash AD, Smith MA, Perry G (2005) Oxidative stress mechanisms and potential therapeutics in Alzheimer disease. J Neural Transm 112, 921-932. (Pubitemid 40869081)
85. Hallgren B, Sourander P (1958) The effect of age on the nonhemin iron in the human brain. J Neurochem 3, 41-51.
86. Crichton RR, Wilmet S, Legssyer R, Ward RJ (2002) Molecular and cellular mechanisms of iron homeostasis and toxicity in mammalian cells. J Inorg Biochem 91, 9-18. (Pubitemid 34727756)
87. Fowler CJ, Wiberg A, Oreland L, Marcusson J, Winblad B (1980) The effect of age on the activity and molecular properties of human brain monoamine oxidase. J Neural Transm 49, 1-20. (Pubitemid 10030548)
88. Cohen G (2000) Oxidative stress, mitochondrial respiration, and Parkinson's disease. Ann N Y Acad Sci 899, 112-120. (Pubitemid 30352780)
89. Reinikainen KJ, Paljarvi L, Halonen T, Malminen O, Kosma VM, Laakso M, Riekkinen PJ (1988) Dopaminergic system and monoamine oxidase-B activity in Alzheimer's disease. Neurobiol Aging 9, 245-252. (Pubitemid 19268089)
90. Berg D (2006) In vivo detection ofiron and neuromelanin by transcranial sonography-anew approach for early detection of substantia nigra damage. J Neural Transm 113, 775-780.
91. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR (1998) Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 158, 47-52. (Pubitemid 28277534)
92. Zatta P, Drago D, Bolognin S, Sensi SL (2009) Alzheimer's disease, metal ions and metal homeostatic therapy. Trends Pharmacol Sci 30, 346-355.
93. Weinreb O, Amit T, Mandel S, Kupershmidt L, Youdim MB (2010) Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities. Antiox Redox Signal 13, 919-949.
94. Zheng H, Gal S, Weiner LM, Bar-Am O, Warshawsky A, Fridkin M, Youdim MB (2005) Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J Neurochem 95, 68-78. (Pubitemid 41384426)
95. Kaur D, Yantiri F, Rajagopalan S, Kumar J, Mo JQ, Boonplueang R, Viswanath V, Jacobs R, Yang L, Beal MF, Di Monte D, Volitaskis I, Ellerby L, Cherny RA, Bush AI, Andersen JK (2003) Genetic or pharmacological iron chela-tion prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37, 899-909. (Pubitemid 36398297)
96. Bush AI (2003) The metallobiology of Alzheimer's disease. Trends Neurosci 26, 207-214. (Pubitemid 36412003)
97. Castellani RJ, Moreira PI, Liu G, Dobson J, Perry G, Smith MA, Zhu X (2007) Iron: the Redox-active center of oxida- tive stress in Alzheimer disease. Neurochem Res 32, 1640-1645. (Pubitemid 47428860)
98. Atwood CS, Scarpa RC, Huang X, Moir RD, Jones WD, Fairlie DP, Tanzi RE, Bush AI (2000) Characterization of copper interactions with Alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42. J Neurochem 75, 1219-1233. (Pubitemid 30660512)
99. Rottkamp CA, Raina AK, Zhu X, Gaier E, Bush AI, Atwood CS, Chevion M, Perry G, Smith MA (2001) Redox-active iron mediates amyloid-beta toxicity. Free Radic Biol Med 30, 447-450. (Pubitemid 32155543)
100. Turnbull S, Tabner BJ, El-Agnaf OM, Moore S, Davies Y, Allsop D (2001) alpha-Synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro. Free Radic Biol Med 30, 1163-1170. (Pubitemid 32441842)
101. Ostrerova-Golts N, Petrucelli L, Hardy J, Lee JM, Farer M, Wolozin B (2000) The A53 T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci 20, 6048-6054. (Pubitemid 30658398)
102. Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M (2003) Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. J Neurochem 87, 172-181. (Pubitemid 37210651)
103. Ono K, Yamada M (2006) Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J Neurochem 97, 105-115.
104. Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, Engemann S, Pastore A, Wanker EE (2008) EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 15, 558-566. (Pubitemid 351799141)
105. Ladiwala AR, Lin JC, Bale SS, Marcelino-Cruz AM, Bhattacharya M, Dordick JS, Tessier PM (2010) Resver-atrol selectively remodels soluble oligomers and fibrils of amyloid Abeta into off-pathway conformers. J Biol Chem 285, 24228-24237.
106. Selkoe DJ (2008) Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 192, 106-113.
107. Periquet M, Fulga T, Myllykangas L, Schlossmacher MG, Feany MB (2007) Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. J Neurosci 27, 3338-3346. (Pubitemid 46474139)
108. Bieschke J, Russ J, Friedrich RP, Ehrnhoefer DE, Wobst H, Neugebauer K, Wanker EE (2010) EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proc Natl Acad Sci USA 107, 7710-7715.
109. Bastianetto S, Yao ZX, Papadopoulos V, Quirion R (2006) Neuroprotective effects of green and black teas and their cat-echin gallate esters against beta-amyloid-induced toxicity. Eur J Neurosci 23, 55-64.
110. Reznichenko L, Amit T, Zheng H, Avramovich-Tirosh Y, Youdim MB, Weinreb O, Mandel S (2006) Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer's disease. J Neurochem 97, 527-536.
111. Rogers JT, Randall JD, Cahill CM, Eder PS, Huang X, Gunshin H, Leiter L, McPhee J, Sarang SS, Utsuki T, Greig NH, Lahiri DK, Tanzi RE, Bush AI, Giordano T, Gullans SR (2002) An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem 277, 45518-45528. (Pubitemid 36159162)
112. Levites Y, Amit T, Mandel S, Youdim MBH (2003) Neuroprotection and neurorescue against amyloid beta toxicity and PKC-dependent release of non-amyloidogenic soluble precusor protein by green tea polyphenol (-)-epigallocatechin-3-gallate. FASEB J17, 952-954.
113. Friedlich AL, Tanzi RE, Rogers JT (2007) The 5'-untrans-lated region of Parkinson's disease alpha-synuclein messen-ger RNA contains a predicted iron responsive element. Mol Psychiatry 12, 222-223. (Pubitemid 46328508)
114. Castellani RJ, Lee HG, Siedlak SL, Nunomura A, Hayashi T, Nakamura M, Zhu X, Perry G, Smith MA (2009) Reexamining Alzheimer's disease: evidence for a protective role for amyloid-beta protein precursor and amyloid-beta. J Alzheimers Dis 18, 447-452.
115. Schofield CJ, Ratcliffe PJ (2004) Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 5, 343-354. (Pubitemid 38579472)
116. Giaccia A, Siim BG, Johnson RS (2003) HIF-1 as a target for drug development. Nat Rev Drug Discov 2, 803-811. (Pubitemid 37361812)
117. Lee DW, Rajagopalan S, Siddiq A, Gwiazda R, Yang L, Beal MF, Ratan RR, Andersen JK (2009) Inhibition of prolyl hydroxylase protects against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson disease. J Biol Chem 284, 29065-29076.
118. Kupershmidt L, Weinreb O, Amit T, Mandel S, Carri MT, Youdim MB (2009) Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. FASEB J 23, 3766-3779.
119. Siddiq A, Aminova LR, Troy CM, Suh K, Messer Z, Semenza GL, Ratan RR (2009) Selective inhibition of hypoxia-inducible factor (HIF) prolyl-hydroxylase 1 mediates neuroprotection against normoxic oxidative death via HIF- and CREB-independent pathways. J Neurosci 29, 8828-8838.
120. Agullo G, Gamet-Payrastre L, Manenti S, Viala C, Remesy C, Chap H, Payrastre B (1997) Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: a comparison with tyrosine kinase and protein kinase C inhibition. Biochem Pharmacol 53, 1649-1657. (Pubitemid 27356094)
121. Wilson WJ, Poellinger L (2002) The dietary flavonoid quercetin modulates HIF-1 alpha activity in endothelial cells. Biochem Biophys Res Commun 293, 446-450. (Pubitemid 34694228)
122. Park SS, Bae I, Lee YJ (2008) Flavonoids-induced accumulation of hypoxia-inducible factor (HIF)-1alpha/2alpha is mediated through chelation of iron. J Cell Biochem 103, 1989-1998. (Pubitemid 351501927)
123. Triantafyllou A, Liakos P, Tsakalof A, Chachami G, Paraskeva E, Molyvdas PA, Georgatsou E, Simos G, Bonanou S (2007) The flavonoid quercetin induces hypoxia-inducible factor-1alpha (HIF-1alpha) and inhibits cell proliferation by depleting intracellular iron. Free Radic Res 41, 342-356. (Pubitemid 46404478)
124. Li Z, Ya K, Xiao-Mei W, Lei Y, Yang L, Ming QZ (2008) Ginkgolides protect PC12 cells against hypoxia-induced injury by p42/p44 MAPK pathway-dependent upregulation of HIF-1alpha expression and HIF-1DNA-binding activity. J Cell Biochem 103, 564-575. (Pubitemid 351171927)
125. Triantafyllou A, Mylonis I, Simos G, Bonanou S, Tsakalof A (2008) Flavonoids induce HIF-1alpha but impair its nuclear accumulation and activity. Free Radic Biol Med 44, 657-670.
126. Jeon H, Kim H, Choi D, Kim D, Park SY, Kim YJ, Kim YM, Jung Y (2007) Quercetin activates an angiogenic pathway, hypoxia inducible factor (HIF)-1-vascular endothelial growth factor, by inhibiting HIF-prolyl hydroxylase: a structural analysis of quercetin for inhibiting HIF-prolyl hydroxylase. Mol Pharmacol 71, 1676-1684. (Pubitemid 47010920)
127. Thomas R, Kim MH (2005) Epigallocatechin gallateinhibits HIF-1alpha degradation in prostate cancer cells. Biochem Biophys Res Commun 334, 543-548. (Pubitemid 40982400)
128. Zhou YD, Kim YP, Li XC, Baerson SR, Agarwal AK, Hodges TW, Ferreira D, Nagle DG (2004) Hypoxia-inducible factor-1 activation by (-)-epicatechin gallate: potential adverse effects of cancer chemoprevention with high-dose green tea extracts. J Nat Prod 67, 2063-2069. (Pubitemid 40092556)
129. Rouault TA (2006) The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat Chem Biol 2, 406-414. (Pubitemid 44114917)
130. Mole DR (2010) Iron homeostasis and its interaction with prolyl hydroxylases. Antioxid Redox Signal 12, 445-458.
131. Hanson ES, Leibold EA (1999) Regulation of the iron regulatory proteins by reactive nitrogen and oxygen species. Gene Expr 7, 367-376. (Pubitemid 29372080)
132. Wang J, Chen G, Muckenthaler M, Galy B, Hentze MW, Pantopoulos K (2004) Iron-mediated degradation of IRP2, an unexpected pathway involving a 2-oxoglutarate-dependent oxygenase activity. Mol Cell Biol 24, 954-965. (Pubitemid 38112161)
133. Kalfon L, Youdim MB, Mandel SA (2007) Green tea polyphenol (-)-epigallocatechin-3-gallate promotes the rapid protein kinase C- and proteasome-mediated degradation of Bad: implications for neuroprotection. J Neurochem 100, 992-1002. (Pubitemid 46213924)
134. Berra E, Municio MM, Sanz L, Frutos S, Diaz-Meco MT, Moscat J (1997) Positioning atypical protein kinase C iso-forms in the UV-induced apoptotic signaling cascade. Mol Cell Biol 17, 4346-4354. (Pubitemid 27318111)
135. Durkin JP, Tremblay R, Chakravarthy B, Mealing G, Morley P, Small D, Song D (1997) Evidence that the early loss of membrane protein kinase C is a necessary step in the excitatory amino acid-induced death of primary cortical neurons. J Neurochem 68, 1400-1412. (Pubitemid 27133047)
136. Vianna MR, Barros DM, Silva T, Choi H, Madche C, Rodrigues C, Medina JH, Izquierdo I (2000) Pharmacological demonstration of the differential involvement of protein kinase C isoforms in short- and long-term memory formation and
137. Lange-Asschenfeldt C, Raval AP, Dave KR, Mochly-Rosen D, Sick TJ, Perez-Pinzon MA (2004) Epsilon protein kinase C mediated ischemic tolerance requires activation of the extracellular regulated kinase pathway in the organotypic hippocampal slice. J Cereb Blood Flow Metab 24, 636-645. (Pubitemid 38725368)
138. Cordey M, Gundimeda U, Gopalakrishna R, Pike CJ (2003) Estrogen activates protein kinase C in neurons: role in neu-roprotection. J Neurochem 84, 1340-1348. (Pubitemid 36343600)
139. Han YS, Zheng WH, Bastianetto S, Chabot JG, Quirion R (2004) Neuroprotective effects of resveratrol against beta-amyloid-induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C. Br J Pharmacol 141, 997-1005. (Pubitemid 38510083)
140. Kumazawa S, Kajiya K, Naito A, Saito H, Tuzi S, Tanio M, Suzuki M, Nanjo F, Suzuki E, Nakayama T (2004) Direct evidence of interaction of a green tea polyphenol, epigallo-catechin gallate, with lipid bilayers by solid-state Nuclear Magnetic Resonance. Biosci Biotechnol Biochem 68, 1743-1747. (Pubitemid 39260305)
141. Kajiya K, Kumazawa S, Naito A, Nakayama T (2008) Solid-state NMR analysis of the orientation and dynamics of epigallocatechin gallate, a green tea polyphenol, incorporated into lipid bilayers. Magn Reson Chem 46, 174-177.
142. Saito H, Tabeta R, Kodama M, Nagata C, Sato Y (1984) Direct evidence of incorporation of 12-O-[20-2 H1]tetrade canoylphorbol-13-acetate into artificial membranesasdeter-mined by deuterium magnetic resonance. Cancer Lett 22, 65-69. (Pubitemid 14133159)
143. Mahmmoud YA (2007) Modulation of protein kinase C by curcumin; inhibition and activation switched by calcium ions. Br J Pharmacol 150, 200-208. (Pubitemid 46160610)
144. Majhi A, Rahman GM, Panchal S, Das J (2010) Binding of curcumin and its long chain derivatives to the activator binding domainofnovel protein kinase C.Bioorg Med Chem 18, 1591-1598.
145. Schroeter H, Bahia P, Spencer JP, Sheppard O, Rat-tray M, Cadenas E, Rice-Evans C, Williams RJ (2007) (-)Epicatechin stimulates ERK-dependent cyclic AMP response element activity and up-regulates Glu R2incortical neurons. J Neurochem 101, 1596-1606. (Pubitemid 46848841)
146. Weinreb O, Mandel S, Youdim MBH (2003) c DNA gene expression profile homology of antioxidants and their anti-apoptotic and pro-apoptotic activities in human neu-roblastoma cells. FASEB J 17, 935-937.
147. Halliwell B (1996) Vitamin C: antioxidant or pro-oxidant in vivo? Free Radic Res 25, 439-454. (Pubitemid 26379060)
148. 2+/calmodulin-dependent protein kinase II, and redox state are involved in epigallocat-echin gallate-induced phospholipase D activation in human astroglioma cells. Eur J Biochem 271, 3470-3480. (Pubitemid 39215337)
149. Mandel S, Maor G, Youdim MB (2004) Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate. J Mol Neu-rosci 24, 401-416. (Pubitemid 41389377)
150. Shimizu S, Narita M, Tsujimoto Y (1999) Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 399, 483-487. (Pubitemid 29258855)
151. Srividhya R, Zarkovic K, Stroser M, Waeg G, Zarkovic N, Kalaiselvi P (2009) Mitochondrial alterations in aging rat brain: effective role of (-)-epigallo catechin gallate. Int J Dev Neurosci 27, 223-231.
152. Schroeder EK, Kelsey NA, Doyle J, Breed E, Bouchard RJ, Loucks A, Harbison A, Linseman DA (2008) Green tea epigallocatechin 3-gallate accumulates in mitochondria and displays a selective anti-apoptotic effect against inducers of mitochondrial oxidative stress in neurons. Antioxid Redox Signal 11, 469-480.
153. Panickar KS, Polansky MM, Anderson RA(2009) Green tea polyphenols attenuate glial swelling and mitochondrial dysfunction following oxygen-glucose deprivation in cultures. Nutr Neurosci 12, 105-113.
154. Selkoe DJ (1991) The molecular pathology of Alzheimer's disease. Neuron 6, 487-498.
155. Mattson MP, Barger SW, Furukawa K, Bruce AJ, Wyss-Coray T, Mark RJ, Mucke L (1997) Cellular signaling roles of TGF beta, TNF alpha and beta APP in brain injury responses and Alzheimer's disease. Brain Res Rev23, 47-61. (Pubitemid 27090749)
156. Small DH, Nurcombe V, Reed G, Clarris H, Moir R, Beyreuther K, Masters CL (1994) A heparin-binding domain in the amyloid protein precursor of Alzheimer's disease is involved in the regulation of neurite outgrowth. J Neurosci 14, 2117-2127. (Pubitemid 24108121)
157. Morimoto T, Ohsawa I, Takamura C, Ishiguro M, Kohsaka S (1998) Involvement of amyloid precursor protein in functional synapse formation in cultured hippocampal neurons. J Neurosci Res 51, 185-195. (Pubitemid 28073026)
158. Obregon DF, Rezai-Zadeh K, Bai Y, Sun N, Hou H, Ehrhart J, Zeng J, Mori T, Arendash GW, Shytle D, Town T, Tan J (2006) ADAM10 activation is required for green tea (-)-epigallocatechin-3-gallate-induced alpha-secretase cleavage of amyloid precursor protein. J Biol Chem 281, 16419-16427.
159. Smith A, Giunta B, Bickford PC, Fountain M, Tan J, Shytle RD (2010) Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease. Int J Pharm 389, 207-212.
160. Choi DS, Wang D, Yu GQ, Zhu G, Kharazia VN, Pare-des JP, Chang WS, Deitchman JK, Mucke L, Messing RO (2006) PKCepsilon increases endothelin converting enzyme activity and reduces amyloid plaque pathology in transgenic mice. Proc Natl Acad Sci U S A 103, 8215-8220. (Pubitemid 43801078)
161. Takeuchi A, Irizarry MC, Duff K, Saido TC, Hsiao Ashe K, Hasegawa M, Mann DM, Hyman BT, Iwatsubo T (2000) Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss. Am J Pathol 157, 331-339. (Pubitemid 30641749)
162. Li R, Peng N, Li XP, Le WD (2006) (-)-Epigallocatechin gallate regulates dopamine transporter internalization via proteinkinase C-dependent pathway.Brain Res1097, 85-89. (Pubitemid 44063491)
163. Lu H, Meng X, Yang CS (2003) Enzymology of methyl-ation of tea catechins and inhibition of catechol-O-methyltransferase by (-)-epigallocatechin gallate. Drug Metab Dispos 31, 572-579. (Pubitemid 36444166)
164. Deleu D, Northway MG, Hanssens Y (2002) Clinical phar-macokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet 41, 261-309. (Pubitemid 34533757)
165. Spencer JP (2008) Food for thought: the role of dietary flavonoidsinenhancing humanmemory, learning andneuro-cognitive performance. Proc Nutr Soc 67, 238-252. (Pubitemid 351543406)
166. Dagda RK, Zhu J, Chu CT (2009) Mitochondrial kinases in Parkinson's disease: converging insights from neurotoxin and genetic models. Mitochondrion 9, 289-298.
167. Satoh T, Nakatsuka D, Watanabe Y, Nagata I, Kikuchi H, Namura S (2000) Neuroprotection by MAPK/ERK kinase inhibition with U0126 against oxidative stress in a mouse neuronal cell line and rat primary cultured cortical neurons. Neurosci Lett 288, 163-166. (Pubitemid 30392436)
168. Chen C, Yu R, Owuor ED, Kong AN (2000) Activation of antioxidant-response element (ARE), mitogen-activated protein kinases (MAPKs) and caspases by major green tea polyphenol components during cell survival and death. Arch Pharm Res 23, 605-612.
169. Impey S, McCorkle SR, Cha-Molstad H, Dwyer JM, Yochum GS, Boss JM, McWeeney S, Dunn JJ, Mandel G, Goodman RH (2004) Defining the CREB regulon: a genome-wide analysis of transcription factor regulatory regions. Cell 119, 1041-1054. (Pubitemid 40037616)
170. Barco A, Bailey CH, Kandel ER (2006) Common molecular mechanisms in explicit and implicit memory. J Neurochem 97, 1520-1533. (Pubitemid 43873650)
171. Kim TI, Lee YK, Park SG, Choi IS, Ban JO, Park HK, Nam SY, Yun YW, Han SB, Oh KW, Hong JT (2009) l-Theanine, an amino acid in green tea, attenuates beta-amyloid-induced cognitive dysfunction and neurotoxicity: reduction in oxidative damage and inactivation of ERK/p38 kinase and NF-kappa B pathways. Free Radic Biol Med 47, 1601-1610.
172. Buccafusco JJ (2009) Multifunctional receptor-directed drugs for disordersofthe central nervous system.Neurother-apeutics 6, 4-13.
173. Sagi Y, Mandel S, Amit T, Youdim MB (2007) Activation of tyrosine kinase receptor signaling pathway by rasagi-line facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol Dis 25, 35-44. (Pubitemid 44765215)
174. Zhu W, Xie W, Pan T, Jankovic J, Li J, Youdim MB, Le W (2008) Comparison of neuroprotective and neu-rorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. J Neurochem 105, 1970-1978. (Pubitemid 351678517)
175. Chen CM, Lin JK, Liu SH, Lin-Shiau SY (2008) Novel regimen through combination of memantine and tea polyphenol for neuroprotection against brain excitotoxicity. J Neurosci Res 86, 2696-2704.
176. Giunta B, Hou H, Zhu Y, Salemi J, Ruscin A, Shytle RD, Tan J (2010) Fish oil enhances anti-amyloidogenic properties of green tea EGCG in Tg2576 mice. Neurosci Lett 471, 134-138.
177. Ma QL, Yang F, Rosario ER, Ubeda OJ, Beech W, Gant DJ, Chen PP, Hudspeth B, Chen C, Zhao Y, Vinters HV, Frautschy SA, Cole GM (2009) Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neu-rosci 29, 9078-9089.
178. Acosta S, Jernberg J, Sanberg CD, Sanberg PR, Small BJ, Gemma C, Bickford PC(2010) NT-020, a Natural Therapeutic Approach to Optimize Spatial Memory Performance and Increase Neural Progenitor Cell Proliferation and Decrease Inflammation in the Aged Rat. Rejuvenation Res 13, 581-588.